Get the Stockscreener App
23.05
0.48%
0.11
Alumis Inc stock is traded at $23.05, with a volume of 910.67K.
It is up +0.48% in the last 24 hours and down -17.97% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
See More
Previous Close:
$22.94
Open:
$23.04
24h Volume:
910.67K
Relative Volume:
0.31
Market Cap:
$2.93B
Revenue:
$24.05M
Net Income/Loss:
$-243.33M
P/E Ratio:
-7.6823
EPS:
-3.0004
Net Cash Flow:
$-370.18M
1W Performance:
-1.37%
1M Performance:
-17.97%
6M Performance:
+419.14%
1Y Performance:
+237.48%
1-Day Range:
$22.65
$23.44
1-Week Range:
$21.00
$23.79
52-Week Range:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
23.05 | 2.93B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Raymond James and Guggenheim stay bullish on Alumis (ALMS) after trial results - MSN
Quarterly Earnings: Is Alumis Inc in a consolidation phaseProduct Launch & Daily Stock Trend Watchlist - baoquankhu1.vn
How Investors Are Reacting To Alumis (ALMS) Psoriasis Drug’s Strong Phase 3 Data And Safety Profile - simplywall.st
ALUMIS INC. unveils psoriasis treatment isolating effects to immune cells only - Traders Union
Deep Track files Schedule 13G reporting 7.36M shares in ALMS (ALMS) - Stock Titan
Risk Analysis: Is Alumis Inc gaining market shareQuarterly Profit Review & High Return Trade Opportunity Guides - baoquankhu1.vn
Alumis Inc. (ALMS) stock price, news, quote and history - Yahoo Finance UK
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results - Yahoo Finance
Alumis (NASDAQ:ALMS) Shares Down 4.1%Here's What Happened - MarketBeat
Why Alumis Inc. Stock Is Dropping After Good News - TipRanks
Form 8-KCurrent report - ADVFN
Why is Alumis stock falling Monday? - MSN
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Psoriasis Results And NDA Plans - Sahm
10 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Yahoo Finance
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Yahoo Finance
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - Stock Titan
Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - Stock Titan
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - Stock Titan
Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - Stock Titan
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans - Sahm
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why Alumis Inc. Shares Are Suddenly Surging - TipRanks
HC Wainwright Brokers Raise Earnings Estimates for Alumis - marketbeat.com
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - The Globe and Mail
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases - BioSpace
FY2027 Earnings Estimate for Alumis Issued By HC Wainwright - MarketBeat
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data - Citeline News & Insights
Oppenheimer Raises Price Target for ALMS, Maintains Outperform R - gurufocus.com
Alumis (ALMS): HC Wainwright & Co. Lowers Price Target, Maintains Buy Rating | ALMS Stock News - GuruFocus
Alumis (ALMS) Maintains "Buy" Rating and Price Target by Chardan Capital | ALMS Stock News - gurufocus.com
Alumis price target raised to $55 from $50 at Oppenheimer - TipRanks
Why Is Alumis Stock Falling Monday? - Benzinga
Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade - MarketBeat
Leerink reiterates Alumis stock rating on consistent trial data - Investing.com UK
US Stocks Recap: Is Alumis Incs growth already priced inTrade Exit Report & Verified Short-Term Plans - baoquankhu1.vn
Leerink reiterates Alumis stock rating on consistent trial data By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Alumis stock after trial data By Investing.com - Investing.com South Africa
Raymond James reiterates Strong Buy on Alumis stock after trial data - Investing.com India
Alumis (NASDAQ:ALMS) Given New $55.00 Price Target at Oppenheimer - MarketBeat
Guggenheim reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Baird reiterates Alumis stock rating on Phase 3 data strength - Investing.com
Guggenheim reiterates Alumis stock rating on psoriasis trial data - Investing.com
Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Envudeucitinib Shows Early, Robust Skin Clearance and Quality of Life Improvements in Phase 3 Plaque Psoriasis Trials by Alumis Inc. 123 - minichart.com.sg
Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating - marketscreener.com
Alumis stock price target lowered to $25 by H.C. Wainwright on competitive pressures - Investing.com India
Stifel reiterates Alumis stock Buy rating after psoriasis data By Investing.com - Investing.com Canada
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):